Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. - Bahlis, Nizar J.; Siegel, David S.; Schiller, Gary J.; Samaras, Christy; Sebag, Michael; Berdeja, Jesus; Ganguly, Siddhartha; Matous, Jeffrey; Song, Kevin; Seet, Christopher S.; Acosta-Rivera, Mirelis; Bar, Michael; et al. (Leukemia & Lymphoma, 2022)